DelMar Pharmaceuticals to Present Interim Clinical Data on VAL-083 in Refractory Glioblastoma at Society for Neuro-Oncology (SNO) Annual Meeting Nov 15, 2012
DelMar CEO Delivers Keynote Address at International Drug Discovery Science and Technology Conference Nov 8, 2012
DelMar Pharmaceuticals to Present New Pre-clinical Data Related to the Mechanism of VAL-083 at the AACR Annual Meeting in April 2012 Feb 7, 2012
DelMar Pharmaceuticals Granted U.S. Orphan Drug Designation for VAL-083 for the Treatment of Glioma Feb 2, 2012
DelMar Pharmaceuticals Receives FDA IND Approval to Begin Clinical Trials with a New Brain Cancer Treatment Sep 6, 2011
